Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsArizona Complete Health trastuzumab Coverage Updat…
    Ask Trek AI about this page
    ModifiedArizona Complete HealthPolicy AZ.CP.PHAR.228

    Herceptin/Biosimilars, Trastuzumab-Hyaluronidase (coverage criteria)

    Customize your policy alerts

    Sign up for Arizona Complete Health Policy AZ.CP.PHAR.228 alerts

    Get alerted when Policy AZ.CP.PHAR.228 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity and prior authorization criteria for trastuzumab, its biosimilars, and trastuzumab-hyaluronidase (Herceptin Hylecta) for Arizona Complete Health Medicaid lines of business (AzCH-CCP and Care1st). Applies to providers prescribing these agents for oncology indications.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Policy Summary
    PayerArizona Complete Health
    PolicyHerceptin/Biosimilars, Trastuzumab-Hyaluronidase
    Policy CodePolicy AZ.CP.PHAR.228
    Change TypeFormulary preference updateadded NCCN-supported off-label indications
    Effective DateApr 15, 2020
    Last ReviewMay 23, 2020
    Next Review Date
    Key ActionObtain prior authorization and submit clinical documentation demonstrating the member meets indication-specific criteria and biosimilar-first requirements when requesting Herceptin or Ontruzant.
    SourceLink
    POLICY UPDATE CHANGES

    Policy updated to make biosimilars preferred and Herceptin non-preferred, with no grandfathering.

    Added qualifiers of 'advanced' and 'recurrent' for gastric, esophageal, or EGJ adenocarcinoma and added additional supported off-label indications per NCCN.

    Specified dose rounding vial recommendations for trastuzumab dosing ranges.

    Herceptin will be non-preferred and listed biosimilars will be preferred (effective 9/1).

    Added gallbladder cancer and cholangiocarcinoma as NCCN-supported off-label indications.

    ≥18Minimum age
    6 monthsTypical initial approval
    12 monthsContinued approval
    Biosimilars preferredFormulary change
    Not allowedGrandfathering

    Coverage Criteria

    Initial Therapy — Breast Cancer

    Initial Approval — Breast Cancer (must meet ALL):

    Breast Cancer Initial Criteria: 1. Diagnosis of HER2-positive breast cancer or leptomeningeal metastases from HER2-positive breast cancer; 2. Prescribed by or in consultation with an oncologist; 3. Age ≥ 18 years; 4. If request is for Herceptin or Ontruzant, member must use ALL of the following unless clinically significant adverse effects occur or all are contraindicated: Herzuma, Kanjinti, Ogivri, Trazimera; 5. Prior authorization is required; 6. Request must meet one of the following: a) For IV products (Herceptin, Ogivri, Herzuma, Ontruzant, Trazimera, Kanjinti): dose does not exceed 8 mg/kg IV for adjuvant therapy or 4 mg/kg IV for treatment of metastatic disease (see Appendix D for dose rounding guidelines); b) Intrathecal administration for leptomeningeal metastasis; c) Herceptin Hylecta SC dose does not exceed 600 mg/10,000 units every 3 weeks; d) Dose/product is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).age >= 18

    Prescribed regimen must be FDA-approved or recommended by NCCN

    Initial Therapy — Gastric/Esophageal/EGJ Cancer

    Initial Approval — Gastric, Esophageal, and EGJ Cancer (must meet ALL):

    Gastric/EGJ Initial Criteria: 1. Diagnosis of HER2-positive advanced, recurrent, or metastatic gastric, esophageal, or EGJ adenocarcinoma; 2. Prescribed by or in consultation with an oncologist; 3. Age ≥ 18 years; 4. Prescribed in combination with a platinum agent (cisplatin or oxaliplatin) and either capecitabine or 5‑fluorouracil; 5. If request is for Herceptin or Ontruzant, member must use ALL of the following unless clinically significant adverse effects occur or all are contraindicated: Herzuma, Kanjinti, Ogivri, Trazimera; 6. Prior authorization is required; 7. Request must meet one of: a) Dose does not exceed 8 mg/kg IV (see Appendix D for dose rounding guidelines); b) Dose/product is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).

    Prescribed regimen must be FDA-approved or recommended by NCCN

    Initial Therapy — Endometrial Carcinoma (off-label)

    Initial Approval — Endometrial Carcinoma (off-label, must meet ALL):

    Endometrial Carcinoma Initial Criteria: 1. Diagnosis of HER2-positive endometrial carcinoma with serous histology; 2. Prescribed by or in consultation with an oncologist; 3. Age ≥ 18 years; 4. Disease is advanced (stage III/IV) or recurrent; 5. Prescribed in combination with carboplatin and paclitaxel; 6. If request is for Herceptin or Ontruzant, member must use ALL of the following unless clinically significant adverse effects occur or all are contraindicated: Herzuma, Kanjinti, Ogivri, Trazimera; 7. Prior authorization is required; 8. Dose is within FDA maximum limit for any FDA-approved indication or is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).

    Off-label — prescriber must submit supporting evidence

    Initial Therapy — Colorectal Cancer (off-label)

    Initial Approval — Colorectal Cancer (off-label, must meet ALL):

    Colorectal Cancer Initial Criteria: 1. Diagnosis of advanced or metastatic colorectal cancer and all of the following: a) Disease is HER2 positive; b) Disease is wild-type RAS (wild-type in both KRAS and NRAS as determined by an FDA-approved test); c) Wild-type BRAF; 2. Prescribed by or in consultation with an oncologist; 3. Age ≥ 18 years; 4. No previous use of a HER2 inhibitor therapy; 5. Prescribed in combination with pertuzumab (Perjeta) or lapatinib (Tykerb); 6. If request is for Herceptin or Ontruzant, member must use ALL of the following unless clinically significant adverse effects occur or all are contraindicated: Herzuma, Kanjinti, Ogivri, Trazimera; 7. Prior authorization is required; 8. Dose is within FDA maximum limit for any FDA-approved indication or is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).

    Off-label — prescriber must submit supporting evidence

    Initial Therapy — Salivary Gland Tumor (off-label)

    Initial Approval — Salivary Gland Tumor (off-label, must meet ALL):

    Salivary Gland Tumor Initial Criteria: 1. Diagnosis of HER2-positive salivary gland tumor; 2. Prescribed by or in consultation with an oncologist; 3. Age ≥ 18 years; 4. Disease is recurrent; 5. Prescribed as one of: a) single agent; b) combination with docetaxel; c) combination with pertuzumab (Perjeta); 6. If request is for Herceptin or Ontruzant, member must use ALL of the following unless clinically significant adverse effects occur or all are contraindicated: Herzuma, Kanjinti, Ogivri, Trazimera; 7. Prior authorization may be required; 8. Dose is within FDA maximum limit for any FDA-approved indication or is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).

    Off-label — prescriber must submit supporting evidence

    Initial Therapy — Gallbladder/Cholangiocarcinoma (off-label)

    Initial Approval — Gallbladder Cancer or Cholangiocarcinoma (off-label, must meet ALL):

    Gallbladder/Cholangiocarcinoma Initial Criteria: 1. Diagnosis of HER2-positive gallbladder cancer or cholangiocarcinoma; 2. Prescribed by or in consultation with an oncologist; 3. Age ≥ 18 years; 4. Disease is unresectable or metastatic; 5. Prescribed in combination with pertuzumab (Perjeta); 6. If request is for Herceptin or Ontruzant, member must use ALL of the following unless clinically significant adverse effects occur or all are contraindicated: Herzuma, Kanjinti, Ogivri, Trazimera; 7. Prior authorization is required; 8. Dose is within FDA maximum limit for any FDA-approved indication or is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).

    Off-label — prescriber must submit supporting evidence

    Initial Therapy — Other Indications

    Initial Approval — Other diagnoses/indications (must meet ALL):

    Other Indications Initial Criteria: 1. Refer to the off-label use policy for the relevant line of business if diagnosis is not specifically listed under Section III (AZ.CP.PMN.53 for Arizona Medicaid); 2. If request is for Herceptin or Ontruzant, member must use ALL of the following unless clinically significant adverse effects occur or all are contraindicated: Herzuma, Kanjinti, Ogivri, Trazimera; 3. Prior authorization is required.

    Off-label requests require reference to off-label policy

    Continued Therapy

    Continued Approval (All indications in Section I — must meet ALL):

    Continued Therapy Criteria: 1. Member currently receiving medication via Centene benefit, or documentation supports current receipt of the requested agent for a covered indication and has received this medication for at least 30 days; 2. Member is responding positively to therapy; 3. If request is for Herceptin or Ontruzant, member must use ALL of the following unless clinically significant adverse effects occur or all are contraindicated: Herzuma, Kanjinti, Ogivri, Trazimera; 4. If request is for a dose increase, request must meet one of the following: a) Breast cancer: i) New dose does not exceed 8 mg/kg IV for adjuvant therapy or 4 mg/kg IV for metastatic disease; ii) Intrathecal administration for leptomeningeal metastases; iii) Herceptin Hylecta SC new dose does not exceed 600 mg/10,000 units every 3 weeks; b) Gastric/EGJ: New dose does not exceed 8 mg/kg IV; c) New dose/product is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).

    Prescribed regimen must be FDA-approved or recommended by NCCN; approval duration for continued therapy: 12 months (or duration of request/6 months depending on section)

    Indication-specific dosing/coverage

    Covered when dosing and indication align with FDA- or NCCN-supported regimens

    Adjuvant breast cancer: Administer trastuzumab (Herceptin or biosimilars) for a total of 52 weeks using loading and maintenance dosing: IV initial 4 mg/kg over 90 minutes then 2 mg/kg weekly during chemotherapy (12–18 weeks depending on regimen), then 6 mg/kg IV every 3 weeks; trastuzumab-hyaluronidase (Hylecta) subcutaneous 600 mg/10,000 units every 3 weeks as specified.52 weeks

    Chunk support: 24,26

    Metastatic breast cancer: As single agent or with paclitaxel: IV initial 4 mg/kg over 90 minutes followed by weekly 2 mg/kg until disease progression; alternative q3week dosing for single-agent maintenance per provider discretion; Hylecta 600 mg/10,000 units SC q3weeks can be used where indicated.until progression

    Chunk support: 26,27

    Metastatic gastric cancer: IV initial 8 mg/kg then 6 mg/kg IV every 3 weeks until disease progression for trastuzumab and listed biosimilars.

    Preference and supported indications (partial)

    Summary from available text

    Formulary preference: Biosimilars are preferred and Herceptin is non-preferred; grandfathering does not apply.

    Effective 9/1 policy update

    Off-label NCCN-supported indications: Gallbladder cancer and cholangiocarcinoma were added as NCCN-supported off-label indications.

    2Q 2023 annual review

    Non‑FDA approved indications that are not specifically addressed within this policy are not authorized for coverage unless the prescriber provides sufficient documentation of efficacy and safety consistent with the off‑label use policy AZ.CP.PMN.53 or the member's evidence of coverage documents.

    Requests for treatment of diagnoses or indications that are not FDA‑approved and are not listed in this policy must be supported by clinical evidence in accordance with the off‑label use policy AZ.CP.PMN.53. Providers must submit supporting literature or guideline documentation with the prior authorization request when relying on off‑label use.

    Grandfathering does not apply to this policy. Effective 9/1 the listed trastuzumab biosimilars are designated as preferred and Herceptin (trastuzumab) will be non‑preferred; members may not retain prior Herceptin coverage under grandfathering provisions.

    Use of trastuzumab for indications not listed in this policy and lacking sufficient off‑label evidence per AZ.CP.PMN.53 may be considered not medically necessary and may be denied.

    Contraindications: none reported in the policy appendices. Boxed warnings applicable to trastuzumab and listed biosimilars include cardiomyopathy, infusion reactions, embryo‑fetal toxicity, and pulmonary toxicity. The subcutaneous formulation (Herceptin Hylecta) carries boxed warnings for cardiomyopathy, embryo‑fetal toxicity, and pulmonary toxicity.

    Coding and Dosing Reference

    Policy identifiermixed
    AZ.CP.PHAR.228Policy reference number (internal policy identifier)
    Referenced HCPCS CodesHCPCS
    J9355Injection, trastuzumab, 10 mg
    J9356Injection, trastuzumab, 10 mg and hyaluronidase-oysk
    Q5112Injection, trastuzumab-dttb, biosimilar, (Ontruzant), 10 mg
    Q5113Injection, trastuzumab-pkrb, biosimilar, (Herzuma), 10 mg
    Q5114Injection, trastuzumab-dkst, biosimilar, (Ogivri), 10 mg
    Q5116Injection, trastuzumab-qyyp, biosimilar, (Trazimera), 10 mg
    Q5117Injection, trastuzumab-anns, biosimilar, (Kanjinti), 10 mg
    Dose limits — IV trastuzumab/biosimilars and Hylecta limits summary
    IV trastuzumab/biosimilars — adjuvant therapyDose does not exceed 8 mg/kg IV (see Appendix D for dose rounding guidelines)
    IV trastuzumab/biosimilars — metastatic diseaseDose does not exceed 4 mg/kg IV (see Appendix D for dose rounding guidelines)
    Herceptin Hylecta (SC)Dose does not exceed 600 mg/10,000 units subcutaneously every 3 weeks (see Appendix D for dose rounding guidelines)
    Dose rounding vial recommendations
    ≤ 157.49 mgVial quantity recommendation = 1 vial of 150 mg
    157.5–314.99 mgVial quantity recommendation = 2 vials of 150 mg

    Provider Actions and Authorization

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for initial and continued use of Herceptin and biosimilars for all indications in this policy. Providers must obtain PA before dispensing/administering the requested agent; approval durations are typically 6 months for initial requests and up to 12 months for continuation requests as specified under Initial and Continued Approval criteria. The policy assists coverage decisions; coverage remains subject to the member's evidence of coverage and other plan terms.

    • Prior authorization required for initial and continuation requests
    • Typical approval duration: 6 months for initial therapy; continuation approvals may be up to 12 months (see policy sections I and II)
    Documentation Required

    Documentation Required for Prior Authorization and Off‑Label Use

    Providers must submit supporting clinical documentation with the PA request (office chart notes, lab results, pathology, diagnostic testing, treatment history, and any peer‑reviewed evidence when requesting off‑label use). Failure to provide adequate documentation may result in denial. For non‑FDA (off‑label) indications, coverage requires documentation consistent with the Health Plan's off‑label policy (AZ.CP.PMN.53 for Arizona Medicaid) or other evidence of efficacy and safety.

    Background

    Trastuzumab is a monoclonal antibody that targets the HER2 (human epidermal growth factor receptor 2) receptor and is indicated for HER2‑overexpressing malignancies. The policy covers IV trastuzumab and multiple approved biosimilars as well as the subcutaneous combination formulation trastuzumab‑hyaluronidase (Herceptin Hylecta). Indications include adjuvant and metastatic HER2‑positive breast cancer and metastatic HER2‑positive gastric/EGJ adenocarcinoma per FDA labeling; select NCCN‑supported off‑label indications (for example, gallbladder cancer and cholangiocarcinoma) are also recognized when supported by appropriate documentation. Note that biosimilars are preferred under the formulary and prior authorization requirements apply.

    Definitions

    Trastuzumab-hyaluronidase (Herceptin Hylecta) — product definition
    ProductHerceptin Hylecta (trastuzumab-hyaluronidase-oysk) — combination of trastuzumab and hyaluronidase for subcutaneous administration
    FormulationSubcutaneous: 600 mg trastuzumab / 10,000 units hyaluronidase per single-dose vial
    UseAlternative to IV trastuzumab for indicated settings per prescribing regimen
    Trastuzumab biosimilars — listed biosimilars names
    Ogivritrastuzumab-dkst
    Herzumatrastuzumab-pkrb
    Ontruzant

    Initial Therapy Criteria

    Initial therapy — diagnosis-specific initial therapy requirements

    Initial therapy requirements vary by diagnosis; must meet indication-specific criteria including oncologist involvement, age ≥ 18, combination regimens where specified, biosimilar-first usage when requesting Herceptin/Ontruzant, prior authorization, and dose limits or literature support for off-label use.

    See coverage criteria by diagnosis: Refer to indication-specific initial approval nodes (Breast, Gastric/EGJ, Endometrial, Colorectal, Salivary gland, Gallbladder/Cholangiocarcinoma, Other) for required documentation and combination therapy requirements.

    Prescribed regimen must be FDA-approved or recommended by NCCN; off-label uses require supporting evidence.

    Initial therapy dosing — dosing depends on indication and product

    Initial dosing depends on indication and product

    IV loading and maintenance dosing: Initial IV dosing commonly includes an 8 mg/kg or 4 mg/kg loading dose depending on indication, with subsequent maintenance dosing of 6 mg/kg IV every 3 weeks or 2 mg/kg weekly per regimen; see adjuvant and metastatic schedules per indication.

    Continuation / Maintenance Criteria

    Continued Therapy

    Continued therapy requirements

    Continued use nodes: 1. Member must be currently receiving the medication via Centene benefit or have documentation of current receipt for at least 30 days; 2. Member must be responding positively to therapy; 3. Biosimilar-first requirement applies when requesting Herceptin/Ontruzant; 4. Dose increases must meet specified dose limits (e.g., ≤ 8 mg/kg IV adjuvant or ≤ 4 mg/kg IV metastatic; Hylecta ≤ 600 mg/10,000 units SC q3weeks) or be supported by practice guidelines/literature (prescriber must submit supporting evidence).

    Continuation therapy dosing — maintenance/continuation dosing rules per indication

    Maintenance/continuation dosing rules per indication

    Adjuvant continuation: After weekly dosing during chemotherapy, continue trastuzumab at 6 mg/kg IV every 3 weeks to complete a total of 52 weeks.

    chunk 24

    Step Therapy / Product Selection

    RequirementDetails / When Applies
    Biosimilar-first requirement when requesting Herceptin or Ontruzant
    If the request is for Herceptin (originator) or Ontruzant, the member must have used ALL listed biosimilars (Herzuma, Kanjinti, Ogivri, Trazimera) unless clinically significant adverse effects occurred or all are contraindicated; applies to initial and continued therapy and must be documented in the prior authorization request.
    Coverage labelPolicy detail
    Herceptin
    Effective 9/1 the listed trastuzumab biosimilars are preferred and Herceptin is non-preferred; formulary preference may result in Herceptin being processed as non-preferred or denied if biosimilars are available and clinically appropriate. Grandfathering does not apply.
    Step therapy / preferenceImplication / Notes
    No explicit sequential step-therapy defined
    Although no stepwise sequence is specified, the payer’s product-selection preference for biosimilars functions operationally as a formulary step: biosimilars should be used when available and appropriate, and requests for non-preferred products (Herceptin) are subject to non‑preferred processing and lack of grandfathering.

    Quantity Limits and Vialing

    Trastuzumab vials — vial quantity recommendations per dose range
    Dose ≤157.49 mgDispense 1 x 150 mg single-dose vial
    157.5–314.99 mgDispense 2 x 150 mg vials
    315–440.99 mgDispense 1 x 420 mg vial
    441–598.49 mgDispense 1 x 150 mg + 1 x 420 mg vials
    Herceptin HylectaDispense 1 x 600 mg (trastuzumab)/10,000 units (hyaluronidase) single-dose vial for SC dosing

    Site of Care

    Billing Rule

    Administration settings — infusion center, office, outpatient, home; Hylecta SC notes

    IV trastuzumab formulations are administered in infusion settings (infusion center, office, hospital outpatient) and may be administered at home where permitted; Herceptin Hylecta is a subcutaneous product given per dosing guidance.

    • Hylecta (Herceptin Hylecta): 600 mg trastuzumab + 10,000 units hyaluronidase SC q3weeks; administer over ~2–5 minutes.
    • IV dosing regimens and site‑of‑care should follow provider and payer site‑of‑care rules.

    Biosimilar Policy Notes

    Billing Rule

    Herceptin (trastuzumab) — HCPCS listing note

    Herceptin (trastuzumab) is listed in the HCPCS/code table; refer to the policy's code list for billing (e.g., J9355/J9356 and Q51xx biosimilar codes).

    • J9355 = injection, trastuzumab, 10 mg; J9356 = injection, trastuzumab, 10 mg and hyaluronidase‑oysk; biosimilar Q51xx codes listed in policy.
    Billing Rule

    Herceptin — preferred use of biosimilars prior to originator/Ontruzant

    When applicable, preferred biosimilars (AHCCCS preferred) should be used prior to Herceptin or Ontruzant; the policy directs use of biosimilars first unless contraindicated.

    • AHCCCS preferred biosimilars include Herzuma, Kanjinti, Ogivri, and Trazimera.
    Billing Rule

    Herceptin — preferred product use reminder

    Reminder: the policy designates preferred biosimilars and non‑preferred Herceptin status; follow the biosimilar‑first requirement when submitting PA requests.

    Policy Summary
    PayerArizona Complete Health
    PolicyHerceptin/Biosimilars, Trastuzumab-Hyaluronidase
    Policy CodePolicy AZ.CP.PHAR.228
    Change TypeFormulary preference updateadded NCCN-supported off-label indications
    Effective DateApr 15, 2020
    Last ReviewMay 23, 2020
    Next Review Date
    Key ActionObtain prior authorization and submit clinical documentation demonstrating the member meets indication-specific criteria and biosimilar-first requirements when requesting Herceptin or Ontruzant.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Dosing ReferenceProvider Actions and AuthorizationBackgroundDefinitionsInitial Therapy CriteriaContinuation / Maintenance CriteriaStep Therapy / Product SelectionQuantity Limits and VialingSite of CareBiosimilar Policy Notes
    until progression

    Chunk support: 28

    315–440.99 mgVial quantity recommendation = 1 vial of 420 mg
    441–598.49 mgVial quantity recommendation = 1 vial of 150 mg + 1 vial of 420 mg
    598.5–881.99 mgVial quantity recommendation = 2 vials of 420 mg
    882–1,039.49 mgVial quantity recommendation = 1 vial of 150 mg + 2 vials of 420 mg
    1,039.5–1,322.99 mgVial quantity recommendation = 3 vials of 420 mg
    • Examples of required documentation: office notes, labs, pathology, diagnostic test results, and treatment history
    • Off‑label requests must include supporting practice‑guideline or peer‑reviewed literature; reference AZ.CP.PMN.53 for Arizona Medicaid
    Step Therapy

    Biosimilar Preference and Step‑Therapy Note

    This policy does not impose explicit step‑therapy (step) rules beyond the biosimilar‑first preference for trastuzumab products. When requesting the originator product (Herceptin) or a specific branded product (e.g., Herceptin Hylecta or Ontruzant), providers must document why biosimilars (listed in the policy) cannot be used—such as contraindications or clinically significant adverse effects. Grandfathering does not apply to Herceptin; requests for non‑preferred originator product may be denied if biosimilar alternatives are appropriate.

    • No separate step‑therapy algorithm is specified in this policy
    • Biosimilars are designated preferred effective 9/1; Herceptin is non‑preferred and grandfathering does not apply
    • If requesting Herceptin/Ontruzant, member must have trialed ALL listed biosimilars unless contraindicated or not tolerated
    Note

    Clinical Judgment and Coverage Conditions

    Providers are expected to exercise professional medical judgment. Coverage decisions require that the prescribed regimen be FDA‑approved or recommended by NCCN; for supported off‑label uses, the prescriber must submit evidence. Coverage is subject to all plan terms, conditions, exclusions, and limitations.

    • Prescribed regimen must be FDA‑approved or recommended by NCCN when applicable
    • For NCCN‑supported off‑label indications, submit supporting evidence with the PA request
    • Coverage decisions are subject to member benefit documents and plan exclusions
    trastuzumab-dttb
    Trazimeratrastuzumab-qyyp
    Kanjintitrastuzumab-anns
    Definition — human epidermal growth factor receptor 2 (HER2)
    TermHER2 = human epidermal growth factor receptor 2
    RelevanceTarget of trastuzumab and biosimilar therapies; overexpression defines eligible indications
    Acronym sourceDefined in Appendix A of the policy
    Definition — esophagogastric junction (EGJ)
    TermEGJ = esophagogastric junction
    ContextUsed to define eligible gastric/EGJ adenocarcinoma indications in the policy
    SourceAppendix A: Abbreviation/Acronym Key
    Formulary preference definition — biosimilars preferred; Herceptin non-preferred
    Formulary statusListed biosimilars (e.g., Herzuma, Kanjinti, Ogivri, Trazimera) are preferred; Herceptin is non-preferred
    GrandfatheringGrandfathering does not apply — Herceptin will be non-preferred effective the policy update
    Implication for requestsRequests for Herceptin or Ontruzant require prior use of listed biosimilars unless contraindicated or intolerant

    Chunks 24,26

    Hylecta SC dosing: Herceptin Hylecta: 600 mg trastuzumab and 10,000 units hyaluronidase administered subcutaneously once every 3 weeks (maximum 600 mg/10,000 units q3weeks).

    Chunk 26

    Metastatic continuation: Continue weekly 2 mg/kg IV until disease progression or per q3week maintenance regimens where applied (e.g., 6 mg/kg q3weeks for maintenance).

    chunks 26,27

    • Requests for Herceptin without biosimilar use must document clinical justification for an exception.
    Billing Rule

    Herceptin — preferred product use reminder (effective 9/1)

    Herceptin is non‑preferred effective 9/1 when listed biosimilars are preferred; there is no grandfathering—members cannot automatically retain Herceptin coverage based on prior use.

    • Plan implemented the formulary preference change effective 9/1 per policy update.
    Billing Rule

    Herceptin — effective 9/1 biosimilars preferred; no grandfathering

    Effective 9/1 the policy update designates biosimilars preferred and Herceptin non‑preferred; grandfathering does not apply to retain Herceptin coverage.

    • Providers should anticipate formulary edits and prior authorization denials for Herceptin when biosimilars are available and appropriate.
    Billing Rule

    Herceptin — biosimilars preferred; no grandfathering

    Biosimilars listed in the policy are preferred and Herceptin is non‑preferred; the policy explicitly states that grandfathering does not apply.

    • AHCCCS preferred: Herzuma, Kanjinti, Ogivri, Trazimera; AHCCCS non‑preferred: Herceptin, Ontruzant, Hylecta.